Active Clinical Trials

Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107

By April 24, 2017 No Comments


Malignant Mesothelioma

Estimated Enrollment: 47

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Observational

Study Design Allocation: Observational Model: Case-Only|Time Perspective: Prospective

Study ID Numbers: CALGB-150509|U10CA031946|CDR0000491313

Study First Received: May 9, 2009

Last Updated: July 1, 2016

Estimated Primary Completion Date: March 2006


Primary Outcome Measures:

Level of biomarkers, including thrombospondin I, vascular endothelial growth factor receptor I, fibroblast growth factor, transforming growth factor, and mesothelin (high vs low)|Effect of biomarker expression level on overall survival

Sponsors and Collaborators:

Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)

Website Link:

Leave a Reply

Call Now ButtonCall Now